Résumé
The 19p13.1 breast cancer susceptibility locus is a modifier of breast cancer risk in BRCA1 mutation carriers and is also associated with the risk of ovarian cancer. Here, we investigated 19p13.1 variation and risk of breast cancer subtypes, defined by estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status, using 48,869 breast cancer cases and 49,787 controls from the Breast Cancer Association Consortium (BCAC). Variants from 19p13.1 were not associated with breast cancer overall or with ER-positive breast cancer but were significantly associated with ER-negative breast cancer risk [rs8170 OR, 1.10; 95% confidence interval (CI), 1.05-1.15; P = 3.49 × 10-5] and triple-negative (ER-, PR-, and HER2-negative) breast cancer (rs8170: OR, 1.22; 95% CI, 1.13-1.31; P = 2.22 × 10-7). However, rs8170 was no longer associated with ERnegative breast cancer risk when triple-negative cases were excluded (OR, 0.98; 95% CI, 0.89-1.07; P = 0.62). In addition, a combined analysis of triple-negative cases from BCAC and the Triple Negative Breast Cancer Consortium (TNBCC; N = 3,566) identified a genome-wide significant association between rs8170 and triple-negative breast cancer risk (OR, 1.25; 95% CI, 1.18-1.33; P=3.31×10-13]. Thus, 19p13.1 is the first triple-negative- specific breast cancer risk locus and the first locus specific to a histologic subtype defined by ER, PR, and HER2 to be identified. These findings provide convincing evidence that genetic susceptibility to breast cancer varies by tumor subtype and that triple-negative tumors and other subtypes likely arise through distinct etiologic pathways.
langue originale | Anglais |
---|---|
Pages (de - à) | 1795-1803 |
Nombre de pages | 9 |
journal | Cancer Research |
Volume | 72 |
Numéro de publication | 7 |
Les DOIs | |
état | Publié - 1 avr. 2012 |
Modification externe | Oui |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: Cancer Research, Vol 72, Numéro 7, 01.04.2012, p. 1795-1803.
Résultats de recherche: Contribution à un journal › Article › Revue par des pairs
TY - JOUR
T1 - 19p13.1 Is a triple-negative-specific breast cancer susceptibility locus
AU - Stevens, Kristen N.
AU - Fredericksen, Zachary
AU - Vachon, Celine M.
AU - Wang, Xianshu
AU - Margolin, Sara
AU - Lindblom, Annika
AU - Nevanlinna, Heli
AU - Greco, Dario
AU - Aittomak̈i, Kristiina
AU - Blomqvist, Carl
AU - Chang-Claude, Jenny
AU - Vrieling, Alina
AU - Flesch-Janys, Dieter
AU - Sinn, Hans Peter
AU - Wang-Gohrke, Shan
AU - Nickels, Stefan
AU - Brauch, Hiltrud
AU - Ko, Yon Dschun
AU - Fischer, Hans Peter
AU - Schmutzler, Rita K.
AU - Meindl, Alfons
AU - Bartram, Claus R.
AU - Schott, Sarah
AU - Engel, Christoph
AU - Godwin, Andrew K.
AU - Weaver, Jo Ellen
AU - Pathak, Harsh B.
AU - Sharma, Priyanka
AU - Brenner, Hermann
AU - Mul̈ler, Heiko
AU - Arndt, Volker
AU - Stegmaier, Christa
AU - Miron, Penelope
AU - Yannoukakos, Drakoulis
AU - Stavropoulou, Alexandra
AU - Fountzilas, George
AU - Gogas, Helen J.
AU - Swann, Ruth
AU - Dwek, Miriam
AU - Perkins, Annie
AU - Milne, Roger L.
AU - Benit́ez, Javier
AU - Zamora, Mariá Pilar
AU - Peŕez, José Ignacio Arias
AU - Bojesen, Stig E.
AU - Nielsen, Sune F.
AU - Nordestgaard, Brøge G.
AU - Flyger, Henrik
AU - Gueńel, Pascal
AU - Truong, Theŕeśe
AU - Menegaux, Florence
AU - Cordina-Duverger, Emilie
AU - Burwinkel, Barbara
AU - Marme, Frederick
AU - Schneeweiss, Andreas
AU - Sohn, Christof
AU - Sawyer, Elinor
AU - Tomlinson, Ian
AU - Kerin, Michael J.
AU - Peto, Julian
AU - Johnson, Nichola
AU - Fletcher, Olivia
AU - Dos Santos Silva, Isabel
AU - Fasching, Peter A.
AU - Beckmann, Matthias W.
AU - Hartmann, Arndt
AU - Ekici, Arif B.
AU - Lophatananon, Artitaya
AU - Muir, Kenneth
AU - Puttawibul, Puttisak
AU - Wiangnon, Surapon
AU - Schmidt, Marjanka K.
AU - Broeks, Annegien
AU - Braaf, Linde M.
AU - Rosenberg, Efraim H.
AU - Hopper, John L.
AU - Apicella, Carmel
AU - Park, Daniel J.
AU - Southey, Melissa C.
AU - Swerdlow, Anthony J.
AU - Ashworth, Alan
AU - Nicholas, Orr
AU - Schoemaker, Minouk J.
AU - Anton-Culver, Hoda
AU - Ziogas, Argyrios
AU - Bernstein, Leslie
AU - Dur, Christina Clarke
AU - Shen, Chen Yang
AU - Yu, Jyh Cherng
AU - Hsu, Huan Ming
AU - Hsiung, Chia Ni
AU - Hamann, Ute
AU - Dun̈nebier, Thomas
AU - Rud̈iger, Thomas
AU - Ulmer, Hans Ulrich
AU - Pharoah, Paul P.
AU - Dunning, Alison M.
AU - Humphreys, Manjeet K.
AU - Wang, Qin
AU - Cox, Angela
AU - Cross, Simon S.
AU - Reed, Malcom W.
AU - Hall, Per
AU - Czene, Kamila
AU - Ambrosone, Christine B.
AU - Ademuyiwa, Foluso
AU - Hwang, Helena
AU - Eccles, Diana M.
AU - Garcia-Closas, Montserrat
AU - Figueroa, Jonine D.
AU - Sherman, Mark E.
AU - Lissowska, Jolanta
AU - Devilee, Peter
AU - Seynaeve, Caroline
AU - Tollenaar, Rob A.E.M.
AU - Hooning, Maartje J.
AU - Andrulis, Irene L.
AU - Knight, Julia A.
AU - Glendon, Gord
AU - Mulligan, Anna Marie
AU - Winqvist, Robert
AU - Pylkas̈, Katri
AU - Jukkola-Vuorinen, Arja
AU - Grip, Mervi
AU - John, Esther M.
AU - Miron, Alexander
AU - Alnsæ, Grethe Grenaker
AU - Kristensen, Vessela
AU - Brøresen-Dale, Anne Lise
AU - Giles, Graham G.
AU - Baglietto, Laura
AU - McLean, Catriona A.
AU - Severi, Gianluca
AU - Kosel, Matthew L.
AU - Pankratz, V. S.
AU - Slager, Susan
AU - Olson, Janet E.
AU - Radice, Paolo
AU - Peterlongo, Paolo
AU - Manoukian, Siranoush
AU - Barile, Monica
AU - Lambrechts, Diether
AU - Hatse, Sigrid
AU - Dieudonne, Anne Sophie
AU - Christiaens, Marie Rose
AU - Chenevix-Trench, Georgia
AU - Beesley, Jonathan
AU - Chen, Xiaoqing
AU - Mannermaa, Arto
AU - Kosma, Veli Matti
AU - Hartikainen, Jaana M.
AU - Soini, Ylermi
AU - Easton, Douglas F.
AU - Couch, Fergus J.
PY - 2012/4/1
Y1 - 2012/4/1
N2 - The 19p13.1 breast cancer susceptibility locus is a modifier of breast cancer risk in BRCA1 mutation carriers and is also associated with the risk of ovarian cancer. Here, we investigated 19p13.1 variation and risk of breast cancer subtypes, defined by estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status, using 48,869 breast cancer cases and 49,787 controls from the Breast Cancer Association Consortium (BCAC). Variants from 19p13.1 were not associated with breast cancer overall or with ER-positive breast cancer but were significantly associated with ER-negative breast cancer risk [rs8170 OR, 1.10; 95% confidence interval (CI), 1.05-1.15; P = 3.49 × 10-5] and triple-negative (ER-, PR-, and HER2-negative) breast cancer (rs8170: OR, 1.22; 95% CI, 1.13-1.31; P = 2.22 × 10-7). However, rs8170 was no longer associated with ERnegative breast cancer risk when triple-negative cases were excluded (OR, 0.98; 95% CI, 0.89-1.07; P = 0.62). In addition, a combined analysis of triple-negative cases from BCAC and the Triple Negative Breast Cancer Consortium (TNBCC; N = 3,566) identified a genome-wide significant association between rs8170 and triple-negative breast cancer risk (OR, 1.25; 95% CI, 1.18-1.33; P=3.31×10-13]. Thus, 19p13.1 is the first triple-negative- specific breast cancer risk locus and the first locus specific to a histologic subtype defined by ER, PR, and HER2 to be identified. These findings provide convincing evidence that genetic susceptibility to breast cancer varies by tumor subtype and that triple-negative tumors and other subtypes likely arise through distinct etiologic pathways.
AB - The 19p13.1 breast cancer susceptibility locus is a modifier of breast cancer risk in BRCA1 mutation carriers and is also associated with the risk of ovarian cancer. Here, we investigated 19p13.1 variation and risk of breast cancer subtypes, defined by estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status, using 48,869 breast cancer cases and 49,787 controls from the Breast Cancer Association Consortium (BCAC). Variants from 19p13.1 were not associated with breast cancer overall or with ER-positive breast cancer but were significantly associated with ER-negative breast cancer risk [rs8170 OR, 1.10; 95% confidence interval (CI), 1.05-1.15; P = 3.49 × 10-5] and triple-negative (ER-, PR-, and HER2-negative) breast cancer (rs8170: OR, 1.22; 95% CI, 1.13-1.31; P = 2.22 × 10-7). However, rs8170 was no longer associated with ERnegative breast cancer risk when triple-negative cases were excluded (OR, 0.98; 95% CI, 0.89-1.07; P = 0.62). In addition, a combined analysis of triple-negative cases from BCAC and the Triple Negative Breast Cancer Consortium (TNBCC; N = 3,566) identified a genome-wide significant association between rs8170 and triple-negative breast cancer risk (OR, 1.25; 95% CI, 1.18-1.33; P=3.31×10-13]. Thus, 19p13.1 is the first triple-negative- specific breast cancer risk locus and the first locus specific to a histologic subtype defined by ER, PR, and HER2 to be identified. These findings provide convincing evidence that genetic susceptibility to breast cancer varies by tumor subtype and that triple-negative tumors and other subtypes likely arise through distinct etiologic pathways.
UR - http://www.scopus.com/inward/record.url?scp=84859375225&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-11-3364
DO - 10.1158/0008-5472.CAN-11-3364
M3 - Article
AN - SCOPUS:84859375225
SN - 0008-5472
VL - 72
SP - 1795
EP - 1803
JO - Cancer Research
JF - Cancer Research
IS - 7
ER -